Delivery Order SPE2DB20D9354-SPE2DB25FX7W9
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $18,238.39 by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Prolastin C 1,000 mg/20 mL vials. This firm fixed-price delivery order, with an ultimate completion date of August 29, 2025, represents a continuation of the company's role as a critical supplier within the federal pharmaceutical supply chain. The award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $18,273.77 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a continuation of DMS Pharmaceutical Group's established role as a critical supplier within the federal pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $18,019.40 by the Defense Logistics Agency (DLA) for the supply of Prolastin C 1,000 mg/20 ml vials. The contract employs firm fixed-price pricing with an ultimate completion date of September 8, 2025. This delivery order was issued without a set-aside designation, reflecting the company's competitive positioning within federal...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. This firm fixed-price delivery order, valued at $18,238.39, was awarded on August 7, 2025, with an ultimate completion date of August 28, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its...
- The Defense Logistics Agency awarded a $18,273.77 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,365.20 contract is for the delivery of Prolastin C, a 1,000 mg/20 ml pharmaceutical product, with a completion date of July 8, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
- This is a $17,974.20 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of PROLASTIN C 1,000 MG/20 ML VLS, a specialized pharmaceutical product, with a period of performance through December 9, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under...
- Defense Logistics Agency awarded DMS Pharmaceutical Group Inc. a firm fixed price delivery order for $14,528.16 to supply 1,000 mg/20 ml vials of Prolastin C. Performance will occur in Park Ridge, Illinois and be completed by December 13, 2023. This order was issued against DMS Pharmaceutical Group's indefinite delivery contract with Defense Logistics Agency to provide pharmaceuticals and medical supplies with a potential value of up to $5 million through December 2025. As a woman-owned small...
- DMS Pharmaceutical Group Inc. has been awarded a firm fixed price delivery order valued at sixteen thousand six hundred ninety-five dollars and thirty cents ($16,695.30) by the Defense Logistics Agency to supply one thousand milligrams per twenty milliliters of Prolastin C injection. The order was awarded on October 25, 2023 and is to be completed by November 16, 2023. No set-aside designation was applied to this procurement. DMS Pharmaceutical Group is a woman-owned small business and...
- This is a $12,249.60 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of the pharmaceutical product Prolastin C (1,000 mg/20 ml vials) to support the recurring medical supply needs of military health facilities. This contract is issued under DMS Pharmaceutical Group's existing indefinite delivery contract...
- SPE2DB20D9354Indefinite Delivery Contract
- SPE2DB20D9354-SPE2DB25FX7W9Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $15,753.25 by the Defense Logistics Agency on August 15, 2025, for the supply of Prolastin C 1,000 mg/20 ml vials. The contract carries a firm fixed-price structure with an ultimate completion date of September 8, 2025, and no set-aside designation was applied to this award. This delivery order will be performed at the vendor's facility in Park Ridge, Illinois. This award represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 through November 2026 under the SPE2DB program. The parent contract enables the Defense Logistics Agency to procure a comprehensive range of pharmaceutical products to support medical supply requirements across Department of Defense healthcare facilities worldwide. Prolastin C, an alpha-1 protease inhibitor augmentation therapy, falls within the contract's scope of specialty pharmaceuticals and biologics. DMS Pharmaceutical Group's consistent selection as a supplier reflects its established position within the federal pharmaceutical supply chain and its capacity to provide critical medications to military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.8k | 8/15/25 |